文献速递糖尿病

钠-葡萄糖协同转运蛋白2抑制剂在住院患者中使用的安全性与有效性:系统综述与Meta分析

A Systematic Review and Meta-analysis on the Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor Use in Hospitalized Patients.
PubMed 文献 · Diabetes Care · 2024-01-01

该系统综述与Meta分析评估住院患者使用SGLT2抑制剂的安全性与有效性,纳入23项RCT共19846例参与者及20项观察性研究。RCT显示SGLT2抑制剂与酮症酸中毒率数值上较高相关但未达统计学显著,与心衰试验中再入院和急诊就诊减少、死亡率降低相关,以及所有RCT中急性肾损伤发生率降低相关;观察性研究未显示不良事件增加。

要点

  • RCT中SGLT2抑制剂组酮症酸中毒率为0.210/100人年,对照组为0.140/100人年,率比1.50(95%CI 0.56-4.23),P=0.38。
  • 心衰试验中SGLT2抑制剂与再入院和急诊就诊减少(OR 0.64,95%CI 0.47-0.86,P<0.01)及死亡率降低(OR 0.74,95%CI 0.56-0.98,P=0.03)相关。
  • 所有RCT中SGLT2抑制剂与急性肾损伤发生率降低相关(OR 0.76,95%CI 0.60-0.97,P=0.03);20项观察性研究未显示不良事件增加。

核心结论

  • 住院患者使用SGLT2抑制剂与酮症酸中毒率数值上较高相关,但需进一步研究。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、Emcare和Cochrane数据库至2024年5月29日,纳入RCT和观察性队列研究。
  • 纳入23项RCT共19846例参与者(29.5%患有2型糖尿病),比较SGLT2抑制剂与安慰剂或活性对照,并分别对RCT和队列研究进行随机效应Meta分析。
  • 纳入20项观察性研究。

主要发现

  • RCT中SGLT2抑制剂组酮症酸中毒率为0.210/100人年(95%CI 0.119-0.370),对照组为0.140/100人年(95%CI 0.070-0.280),率比1.50(95%CI 0.56-4.23),P=0.38。
  • 心衰试验中SGLT2抑制剂与再入院和急诊就诊减少相关(OR 0.64,95%CI 0.47-0.86,P<0.01),与死亡率降低相关(OR 0.74,95%CI 0.56-0.98,P=0.03)。
  • 所有RCT中SGLT2抑制剂与急性肾损伤发生率降低相关(OR 0.76,95%CI 0.60-0.97,P=0.03)。
  • 20项观察性研究未显示不良事件增加。

局限性

  • 酮症酸中毒率较低,可能导致缺乏检测显著差异的效力。
  • 需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in hospitalized patients are unclear. PURPOSE: To evaluate outcomes of inpatient SGLT2 inhibitor use. DATA SOURCES: MEDLINE, Embase, Emcare, and Cochrane databases were searched through 29 May 2024. STUDY SELECTION: Randomized controlled trials (RCTs) and observational cohort studies with assessment of SGLT2 inhibitor use in patients hospitalized for any reason were included. DATA EXTRACTION: Study characteristics and clinical outcomes were extracted. DATA SYNTHESIS: We performed a random-effects meta-analysis analyzing RCTs and cohort studies separately. Heterogeneity was quantified with the I2 statistic. Twenty-three RCTs comprising 19,846 participants (29.5% with type 2 diabetes) with comparison of SGLT2 inhibitors with placebo or active comparator were included. Ketoacidosis rates were 0.210 per 100 person-years (95% CI 0.119, 0.370) for SGLT2 inhibitors and 0.140 per 100 person-years (95% CI 0.070, 0.280) for control (rate ratio 1.50 [95 CI 0.56, 4.23], P = 0.38). SGLT2 inhibitor use was associated with fewer readmissions and urgent visits (odds ratio [OR] 0.64 [95 CI 0.47, 0.86], P < 0.01) and lower mortality rates (OR 0.74 [95% CI 0.56, 0.98], P = 0.03) in heart failure trials and lower incidence of acute kidney injury (OR 0.76 [95% CI 0.60, 0.97], P = 0.03) among all RCTs. Twenty observational studies were included and did not show increased adverse events. LIMITATIONS: Ketoacidosis rates were low, likely leading to lack of power to detect significant differences. CONCLUSIONS: SGLT2 inhibitor use among hospitalized patients was associated with numerically higher rates of ketoacidosis, although further studies are required.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Gao FM, Ali AS, Bellomo R, et al. A Systematic Review and Meta-analysis on the Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor Use in Hospitalized Patients. Diabetes Care. 2024. PMID: 39602586. doi:10.2337/dc24-0946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。